Edition:
India

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
19 Jan 2018
Change (% chg)

$-0.05 (-2.66%)
Prev Close
$1.88
Open
$1.89
Day's High
$1.89
Day's Low
$1.82
Volume
14,840
Avg. Vol
103,671
52-wk High
$2.82
52-wk Low
$0.90

Select another date:

Wed, Nov 8 2017

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

BRIEF-Second sight receives German approval to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients

* Second Sight receives approval from Bundesinstitut Für Arzneimittel Und Medizinprodukte in Germany to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives conditional FDA approval to begin first Orion human clinical study

* Second sight receives conditional FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products Q2 sales $2.2 mln

* Says total revenue was $2.2 million for q2 of 2017, compared with $1.0 million in q2 of 2016 Source text for Eikon: Further company coverage:

Select another date: